Sign up USA
Proactive Investors - Run By Investors For Investors

Summit Therapeutics boss to speak at DMD conference

CEO Glyn Edwards is to participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference
DMD
DMD is a wasting disease that primarily affects boys and young men

Glyn Edwards, chief executive officer of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), is to speak at a New York life sciences conference this month.

The boss of the dual-listed drug discovery and development company, which is focused on advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017.

Edwards will also participate in one-to-one meetings at the conference. 

John-H.jpg
Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

brain-scan.jpg
May 22 2017
In the six months ended March, revenues increased 31% to £2mln
Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
Picture of drugs
January 25 2017
Gross profit in the half year to December was up by 34%
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use